

Will Tariffs Affect Injectables Like Botox and Ozempic?


Garrett Munce

May 7, 2025 • 5 min read



Will Tariffs Affect Injectables? Hearst Owned

For the last few months, not a day has gone by where tariffs haven't been on the tip of everyone's tongue. The economic uncertainty created by President Trump's one-day-they're-in-the-next-day-they're-out tariff strategy is causing global upheaval on an extreme scale, with the potential to increase prices of everything across the board. And while the price of things like eggs, cars and iPhones are getting headlines, in certain circles, one of the biggest questions remains: *will the tariffs make my Botox more expensive?*



The short answer is, possibly. But it's complicated because, like everything else regarding the tariffs, the answer isn't exactly clear. "Everybody is trying to be ready for when something does happen, but really nothing has come through yet where people are seeing actual bills on the healthcare side of things," says [Sean McNally, MD](#), a board-certified plastic surgeon in Portland, OR. Part of the confusion is how these products are classified. Neuromodulators like Botox, Xeomin, Dysport and Daxxify are classified as drugs under the FDA, whereas hyaluronic fillers like Juvederm and Restylane are classified as medical devices,

which may be more likely to be subject to tariffs. “I’ve heard wind that medications are not going to be hit with tariffs, however when I looked at the list of things that they say are not going to be tarified, I didn’t see drugs on it,” he says.



4.10% APY ^①
Member FDIC

12 - MONTH CERTIFICATE OF DEPOSIT
Open your CD account, make a deposit and start earning.

[GET STARTED](#)



360 CHECKING
Member FDIC

Earn a \$250 bonus with 360 Checking.
No fees, no minimums. Terms apply.

[OPEN ACCOUNT](#)

powered by GOBankingRates

Provenance is another factor. AbbVie, the maker of Botox, produces their neuromodulator in Ireland; Galderma produces most their products like neuromodulator Dysport and filler Restylane in France, Sweden and the UK; Jueveau, a neuromodulator distributed by Evolus, is from South Korea. Should there be lasting tariffs on any of these countries, says Dr. McNally, these could be affected. To date, Daxxify is the only neuromodulator that is made in the United States. Should foreign-made products become subject to tariffs, we may also see some providers start to prioritize U.S.-made alternatives.

Geography is a major player in potential tariffs on GLP-1 drugs like Ozempic and Wegovy, as well. Novo Nordisk, the makers of the increasingly popular drugs, is based in Denmark and while no tariffs have been enacted yet on Denmark specifically, a blanket European Union tariff would still affect them (not to mention President Trump’s desire to annex Greenland, which is controlled by Denmark). Officially, the company is monitoring the situation, but CEO Lars Jorgensen [recently said](#) that tariffs could force them to increase prices on the products that many people are already paying a premium for. (Novo Nordisk is building a new factory in North Carolina, but that is still years away from being operational.)

[Story Continues](#)

[View Comments](#)

[Terms and Privacy Policy](#) [Privacy Dashboard](#)

